ZAMI 1305

01/01/1986 - "Further studies on the tumor-initiating activity of the beta-blocker DL-ZAMI 1305."
11/01/1984 - "Tumor-initiating activity of the beta-blocker ZAMI 1305 in the liver of the female Wistar rat."
10/01/1985 - "These results are suggestive of a possible tumor-promoting activity of DL-ZAMI 1305; in vivo studies on this carcinogen are in progress."
10/01/1985 - "Influence on cell-cell communication (dye-transfer) of the oncogenic beta-blocker DL-ZAMI 1305: possible relation to tumor promotion."
04/01/1982 - "When an isomer of ZAMI 1305, DL-1-(2-nitro-5-methyl-phenoxy)-3-tert-butylamino-propan-2-ol (ZAMI 1327), and DL-practolol, which have pharmacologic activities similar to those of ZAMI 1305, were administered by the same experimental technique as used for ZAMI 1305, no liver tumors appeared either in male or female rats."

01/01/1984 - "An increase of relative thyroid weight, coupled with histological hyperplasia of the gland, is observed in female Wistar rats treated for 6 months with ZAMI 1305. "
07/01/1983 - "A significant high incidence of cases with thyroid hyperplasia is found among female rats, the only sex susceptible to the carcinogenic effect of ZAMI 1305. "
11/01/1984 - "A 1-week treatment with the hepatocarcinogen beta-blocker DL-1-(2-nitro-3-methyl-phenoxy)-3-tert-butylamino-propan-2-ol (ZAMI 1305) induces the appearance of preneoplastic liver lesions--oval cell hyperplasia, basophilic and gamma-glutamyltranspeptidase positive (GGT+) foci--in female Wistar rats, as evidenced by the Solt and Farber short-term test of carcinogenesis. "
12/01/1984 - "ZAMI 1305 administration to female rat induces also: (i) an increase of the relative liver weight, of the DNA and RNA synthesizing activity; (ii) a decrease of the number of hepatocytes in mitosis; (iii) a minimal oval cell hyperplasia. "

11/01/1984 - "A 1-week treatment with the hepatocarcinogen beta-blocker DL-1-(2-nitro-3-methyl-phenoxy)-3-tert-butylamino-propan-2-ol (ZAMI 1305) induces the appearance of preneoplastic liver lesions--oval cell hyperplasia, basophilic and gamma-glutamyltranspeptidase positive (GGT+) foci--in female Wistar rats, as evidenced by the Solt and Farber short-term test of carcinogenesis. "

04/01/1982 - "A newly synthesized beta-adrenoreceptor blocking agent, DL-1-(2-nitro-3-methyl-phenoxy)-3-tert-butylamino-propan-2-ol (ZAMI 1305), administered intragastrically for 6 months induced hepatocellular carcinomas in female outbred Wistar rats in a dose-dependent fashion but was harmless to the livers of male outbred Wistar rats. "

01/01/1986 - "Female Wistar rats were given a single dose 150 mg/kg of body weight of DL-ZAMI 1305 by gavage 24 hours before or 24 hours after partial hepatectomy. "